Jack L. Wyszomierski Sells 8,768 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski sold 8,768 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the sale, the director now directly owns 356,605 shares in the company, valued at approximately $13,479,669. This represents a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Exelixis Stock Up 2.8 %

EXEL stock opened at $38.69 on Friday. The company’s 50-day simple moving average is $34.53 and its 200-day simple moving average is $31.66. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $38.72. The firm has a market cap of $10.83 billion, a P/E ratio of 21.86, a PEG ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on EXEL. Piper Sandler boosted their price objective on shares of Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Guggenheim reiterated a “buy” rating and set a $42.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a report on Thursday, February 13th. Citigroup lifted their target price on Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Finally, UBS Group increased their price target on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.24.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Exelixis by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock valued at $979,994,000 after acquiring an additional 121,750 shares during the period. LSV Asset Management lifted its holdings in Exelixis by 0.8% during the fourth quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company’s stock valued at $272,056,000 after purchasing an additional 67,470 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in Exelixis by 10.2% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company’s stock valued at $254,110,000 after purchasing an additional 708,312 shares in the last quarter. Invesco Ltd. increased its stake in shares of Exelixis by 308.1% during the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after purchasing an additional 3,001,204 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Exelixis by 25.7% during the fourth quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company’s stock worth $132,101,000 after purchasing an additional 810,857 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.